NEW YORK, NY / ACCESSWIRE / September 28, 2022 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
MNSO Shareholders Click Here: https://www.zlk.com/pslra-1/miniso-class-action-loss-submission-form?prid=32168&wire=1
TSP Shareholders Click Here: https://www.zlk.com/pslra-1/tusimple-lawsuit-loss-submission-form?prid=32168&wire=1
FLGT Shareholders Click Here: https://www.zlk.com/pslra-1/fulgent-genetics-lawsuit-loss-submission-form?prid=32168&wire=1
* ADDITIONAL INFORMATION BELOW *
![Levi & Korsinsky, LLP, Wednesday, September 28, 2022, Press release picture](https://www.accesswire.com/users/newswire/images/717810/rotating-logo.jpg)
MINISO Group Holding Limited (NYSE:MNSO)
This lawsuit is on behalf of persons or entities who purchased or otherwise acquired publicly traded MINISO securities pursuant and/or traceable to the registration statement and related prospectus issued in connection with MINISO's October 2020 initial public offering.
Lead Plaintiff Deadline : October 17, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/miniso-class-action-loss-submission-form?prid=32168&wire=1
According to the filed complaint, (1) defendants and other undisclosed related parties owned and controlled a much larger amount of MINISO stores than previously stated; (2) as a result, MINISO concealed its true costs; (3) the Company did not represent its true business model; (4) defendants, including the Company and its chairman, engaged in planned unusual and unclear transactions; (5) as a result of at least one of these transactions, the Company is at risk of breaching contracts with People's Republic of China authorities; (6) the Company would imminently and drastically drop its franchise fees; and (7) as a result, defendant's statements about the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
TuSimple Holdings Inc. (NASDAQ:TSP)
This lawsuit is on behalf of all persons who: (a) purchased or otherwise acquired TuSimple common stock pursuant and/or traceable to documents issued in connection with TuSimple's April 15, 2021 initial public offering; and/or (b) that purchased or otherwise acquired TuSimple securities between April 15, 2021 and August 1, 2022, both dates inclusive.
Lead Plaintiff Deadline : October 31, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/tusimple-lawsuit-loss-submission-form?prid=32168&wire=1
According to the filed complaint, (i) TuSimple's commitment to safety was significantly overstated and defendants concealed fundamental problems with the Company's technology; (ii) TuSimple was rushing the testing of its autonomous driving technology in order to deliver driverless trucks to the market ahead of its more safety-conscious competitors; (iii) there was a corporate culture within TuSimple that suppressed or ignored safety concerns in favor of unrealistically ambitious testing and delivery schedules; (iv) the aforementioned conduct made accidents involving the Company's autonomous driving technology more likely; (v) the aforementioned conduct invited enhanced regulatory scrutiny and investigatory action toward the Company; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Fulgent Genetics, Inc. (NASDAQ:FLGT)
FLGT Lawsuit on behalf of: investors who purchased March 22, 2019 - August 4, 2022
Lead Plaintiff Deadline : November 21, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/fulgent-genetics-lawsuit-loss-submission-form?prid=32168&wire=1
According to the filed complaint, during the class period, Fulgent Genetics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Fulgent had been conducting medically unnecessary laboratory testing, engaging in improper billing practices in relation to laboratory testing, and providing or receiving remuneration in violation of the Anti-Kickback Statute and Stark Law; (ii) accordingly, Fulgent was likely to become subject to enhanced legal and regulatory scrutiny; (iii) Fulgent's revenues, to the extent they were derived from the foregoing unlawful conduct, were unsustainable; (iv) the foregoing, once revealed, was likely to subject the Company to significant financial and/or reputational harm; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
SOURCE: Levi & Korsinsky, LLP